Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1146-1153

  Mehta, Gautam U ^a   Shively, Sharon B ^a,b   Duong, Heng ^a   Tran, Maxine G B ^c   Moncrief, Travis J ^a   Smith, Jonathan H ^a   Li, Jie ^a   Edwards, Nancy A ^a   Lonser, Russell R ^a   Zhuang, Zhengping ^a   Merrill, Marsha J ^a   Raffeld, Mark ^d   Maxwell, Patrick H ^e   Oldfield, Edward H ^a   Vortmeyer, Alexander O ^a,f  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Cambridge Research Institute   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANAMNESIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; EPIDIDYMIS DISEASE; GENE DELETION; GONAD DEVELOPMENT; HAMARTOMA; MESONEPHROS; PRIORITY JOURNAL; TESTIS TUMOR; VON HIPPEL LINDAU DISEASE;

EID: 54249160023     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08476     Document Type: Article

References (31)

1. Melmon KL and Rosen SW (1964). Lindau's disease: review of literature and study of a large kindred. Am J Med 36, 595-617.
2. Price EB Jr (1971). Papillary cystadenoma of the epididymis. A clinicopathologic analysis of 20 cases. Arch Pathol Lab Med 91, 456-470.
3. 2+-transporting ATPase isoform 2 gene that resides in the von Hippel-Lindau gene region. Cancer Res 53, 861-867.
4. Gläsker S, Tran MGB, Shively SB, Ikejiri B, Lonser RR, Maxwell PH, Zhuang Z, Oldfield EH, and Vortmeyer AO (2006). Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. J Pathol 210, 32-41.
5. Vortmeyer AO, Tran M, Zeng W, Glasker S, Riley C, Tsokos M, Ikejiri B, Merrill MJ, Raffeld M, Zhuang Z, et al. (2006). Evolution of VHL tumorigenesis in nerve root tissue. J Pathol 210, 374-382.
6. Vortmeyer AO, Yuan Q, Lee YS, Zhuang Z, and Oldfield EH (2004). Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 55, 721-728.
7. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, and Harris AL (2000). The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157, 411-421.
8. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, and Oldfield EH (1993). Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91, 153-159.
9. Suchanek detection of mRNA on paraffin-embedded material of the central nervous system with DIG-labeled RNA probes. Nonradioactive In Situ Hybridization Application Manual, pp. 164-168. Roche Diagnostics Corporation.
10. Burkitt HG, Young B, and Heath JW (1993). Male reproductive system. Wheater's Functional Histology 3rd ed., pp. 323-334. London: Churchill Livingstone.
11. Lindau A (1926). Studien uber kleinhirnzysten. Bau, pathogenese und beziehung zur angiomatosis retinae. Acta Path et Microbiol Scand (Suppl 1), 1-126.
12. Magro G, Perris R, Romeo R, Marcello M, Lopes M, Vasquez E, and Grasso S (2001). Comparative immunohistochemical analysis of the expression of cytokeratins, vimentin, and alpha-smooth muscle actin in human foetal mesonephros and metanephros. Histochem J 33, 221-226.
13. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, and Zhuang Z (1996). Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 149, 2089-2094.
14. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, et al. (2002). HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468.
15. Gläsker S, Lonser RR, Tran MGB, Ikejiri B, Butman JA, Zeng W, Maxwell PH, Zhuang Z, Oldfield EH, and Vortmeyer AO (2005). Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res 65, 10847-10853.
16. Richards FM, Schofield PN, Fleming S, and Maher ER (1996). Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5, 639-644.
17. Pause A, Lee S, Worrell RA, Chen DY, Burgess WH, Linehan WM, and Klausner RD (1997). The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 94, 2156-2161.
18. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, and Kaelin WG Jr (1998). Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol 18, 732-741.
19. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, and Krek W (1999). The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13, 1822-1833.
20. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
21. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, and Maxwell PH (2000). Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275, 25733-25741.
22. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, and Kaelin WG (2000). Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2, 423-427.
23. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, and Goldberg MA (1996). Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93, 10595-10599.
24. Krieg M, Haas R, Brauch H, Acker T, Flamme I, and Plate KH (2000). Upregulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443.
25. Nanka O, Valasek P, Dvorakova M, and Grim M (2006). Experimental hypoxia and embryonic angiogenesis. Dev Dyn 235, 723-733.
26. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL, and Ratcliffe PJ (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25, 5675-5686.
27. Rubin E and Farber JL (1999). Pathology. 3rd ed. Philadelphia, PA: Lippincott Raven.
28. Majno G and Joris I (2004). Cells, Tissue, and Disease: Principles of General Pathology. 2nd ed. New York, NY: Oxford University Press.
29. Stevens A and Lowe JS (2000). Pathology: Illustrated Review in Color. 2nd ed. St. Louis, MO: Mosby.
30. Kumar V, Abbas AK, and Fausto N (2005). Robbins and Cotran. Pathologic Basis of Disease. Philadelphia, PA: Elsevier Saunders.
31. Chandrasoma P and Taylor CR (1998). Concise Pathology. 3rd ed. Norwalk, CT: Appleton & Lange.